Ligatin Tablet

Linagliptin
5mg
Royal Pharmaceuticals Pvt. Ltd
Pack size
Dispensing mode
Source
Agent
Retail Price 20.00 NPR

Available as:

Indications

Ligatin Tablet is used for: Type 2 Diabetes Mellitus

Adult Dose

Oral Type 2 diabetes mellitus Adult: 5 mg once daily. Indicated for adults with diabetes mellitus type II along with diet and exercise to lower blood sugar; may be used as monotherapy or in combination with other common antidiabetic medications including metformin, sulfonylurea, pioglitazone, or insulin. Elderly: No dose adjustment is necessary based on age. Hepatic or renal impairment: No dosage adjustment required.

Child Dose

Safety and efficacy not established

Renal Dose

Renal Impairment: No dose adjustment.

Administration

May administer with or without food

Contra Indications

Patients with a history of a hypersensitivity reaction to linagliptin, such as urticaria, angioedema, or bronchial hyperreactivity. Type 1 DM. Treatment of diabetic ketoacidosis.

Precautions

Concomitant use w/ sulphonylureas which are known to cause hypoglycemia; dose reduction of sulphonylureas may be considered. May affect ability to drive or operate machinery. Childn. Elderly >75 yr. Pregnancy & lactation. Lactation: Unknown whether distributed in breast milk; caution advised

Pregnancy-Lactation

Interactions

Increased risk of hypoglycaemia when used w/ an insulin secretagogue (e.g. sulfonylurea) or insulin. Plasma concentration of linagliptin may be decreased by strong inducers of P-glycoprotein (e.g. rifampicin) and may be increased by strong P-glycoprotein inhibitors (e.g. ritonavir).

Adverse Effects

Side effects of Linagliptin : 1-10% Nasopharyngitis (4.3%),Hyperlipidemia (2.8%; with pioglitazone),Cough (2.4%; with metformin and sulfonylurea),Hypertriglyceridemia (2.4%; with sulfonylurea),Weight gain (2.3%; with pioglitazone), Hypoglycemia 7.6% overall incidence, 22.9% incidence compared with placebo plus metformin and a sulfonylurea Incidence similar to placebo with monotherapy or combined with metformin or pioglitazone

Mechanism of Action

Dipeptidyl peptidase 4 (DPP-4) inhibitor; increases and prolongs incretin hormone activity which is inactivated by DPP-4 enzyme. Incretins regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cells .

Note

Ligatin 5mg Tablet manufactured by Royal Pharmaceuticals Pvt. Ltd. Its generic name is Linagliptin. Ligatin is availble in Nepal. Farmaco Nepal drug index information on Ligatin Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Linagliptin :